NCT03677934已完成3 期
Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 415
- 试验地点
- 75
- 主要终点
- Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score at the Average of Week 36 and Week 40, as Assessed Using the ETDRS Visual Acuity Chart at a Starting Distance of 4 Meters
研究概览
简要总结
Study GR40548 is a Phase III, randomized, multicenter, open-label (visual assessor [VA]-masked), active-comparator study designed to assess the efficacy, safety, and pharmacokinetics (PK) of 100mg/ml delivered via the Port Delivery System with ranibizumab (PDS) compared with ranibizumab intravitreal injections at 0.5 mg (10 mg/mL) in participants with neovascular age-related macular degeneration (nAMD).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥50 years, at time of signing Informed Consent Form
- •Initial diagnosis of exudative neovascular age-related macular degeneration (nAMD) within 9 months prior to the screening visit
- •Previous treatment with at least three anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections for nAMD per standard of care within 6 months prior to the screening visit
- •Demonstrated response to prior anti-VEGF intravitreal treatment since diagnosis
- •Best-corrected visual acuity (BCVA) of 34 letters or better
排除标准
- •Subfoveal fibrosis or subfoveal atrophy in study eye
- •Subretinal hemorrhage that involves the center of the fovea in study eye
- •History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in study eye
- •Prior treatment with Visudyne®, external-beam radiation therapy, or transpupillary thermotherapy in study eye
- •Previous intraocular device implantation in study eye
- •Previous laser (any type) used for AMD treatment in study eye
- •Treatment with anti-VEGF agents other than ranibizumab within 1 month prior to the randomization visit in either eye
- •Prior participation in a clinical trial involving anti-VEGF drugs within 6 months prior to the randomization visit, other than ranibizumab in either eye
- •CNV due to other causes, such as ocular histoplasmosis, trauma, or pathologic myopia in either eye
- •Uncontrolled blood pressure
- •History of stroke within the last 3 months prior to informed consent
- •Uncontrolled atrial fibrillation within 3 months of informed consent
- •History of myocardial infarction within the last 3 months prior to informed consent
- •History of other disease, metabolic dysfunction, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of ranibizumab or placement of the Implant and that might affect interpretation of the results of the study or renders the participant at high risk of treatment complications in the opinion of the investigator
- •Current systemic treatment for a confirmed active systemic infection
- •Chronic use of oral corticosteroids
- •Active cancer within 12 months of randomization
- •Previous participation in any non-ocular (systemic) disease studies of investigational drugs within 1 month preceding the informed consent (excluding vitamins and minerals)
研究组 & 干预措施
PDS Implant Arm
Experimental
Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals
干预措施: PDS Implant filled with 100 mg/mL Ranibizumab (Drug)
Intravitreal Arm
Active Comparator
Participants will receive ranibizumab 0.5 mg monthly intravitreal injections of 10 mg/mL formulation at Day 1 and every month thereafter.
干预措施: Intravitreal Injections of 10 mg/mL Ranibizumab (Drug)
结局指标
主要结局
Change From Baseline in Best-Corrected Visual Acuity (BCVA) Score at the Average of Week 36 and Week 40, as Assessed Using the ETDRS Visual Acuity Chart at a Starting Distance of 4 Meters
时间窗: Baseline, and the average of Week 36 and Week 40
The primary efficacy endpoint is the change in BCVA score from baseline averaged over Weeks 36 and 40 with BCVA assessed using the ETDRS chart at a starting distance of 4 meters. ETDRS = Early Treatment Diabetic Retinopathy Study. The primary objective is to determine the NI and equivalence between the two treatment groups, as measured by the primary efficacy endpoint with a NI margin of 4.5 letters and equivalence margins of ± 4.5 letters. A vision score of 20/20 vision is considered normal. A score of 20/200 is considered being legally blind.
次要结局
- Change From Baseline in BCVA Score Averaged Over Week 60 and Week 64(Baseline, Week60, Week 64)
- Change From Baseline in BCVA Score Over Time(Baseline up to Week 96)
- Percentage of Participants Who Lose <10 or <5 Letters in BCVA Score From Baseline to the Average Over Week 36 and Week 40(Baseline, and the average of Week 36 and Week 40)
- Percentage of Participants Who Gain ≥0 Letters in BCVA Score From Baseline Over Time(Baseline up to Week 96)
- Change From Baseline in CPT Over Time(Baseline up to Week 96)
- Percentage of Participants With Ocular and Systemic (Non-Ocular) AEs(Randomization to Week 96)
- Percentage of Participants With Adverse Events of Special Interest(Randomization to Week 96)
- Observed Serum Ranibizumab Concentrations at Specified Timepoints(Randomization to Week 96)
- Percentage of Participants in the PDS Implant Arm Who Undergo Supplemental Treatment With Intravitreal Ranibizumab 0.5 mg Before the First, Second, Third, and Fourth Fixed Refill-Exchange Intervals(Day 1 to Week 24, Week 25 to Week 48, Week 49 to Week 72, Week73 to Week 96)
- Percentage of Participants With BCVA Score of 38 Letters (20/200 Approximate Snellen Equivalent) or Worse Over Time(Baseline up to Week 96)
- Percentage of Participants With BCVA Score of 69 Letters (20/40 Approximate Snellen Equivalent) or Better at the Average Over Week 36 and Week 40(Baseline, and the average of Week 36 and Week 40)
- Percentage of Participants With BCVA Score of 69 Letters (20/40 Approximate Snellen Equivalent) or Better Over Time(Baseline up to Week 96)
- Percentage of Participants Who Gain ≥0 Letters in BCVA Score From Baseline to the Average Over Week 36 and Week 40(Baseline up to Week 40)
- Percentage of Participants in the PDS Implant Arm Who Undergo a Supplemental Treatment That Requires Subsequent Additional Supplemental Treatments During the Study(Week 16 to Week 92)
- Estimated PK Parameter Values AUC0-6M(Randomization to Week 96)
- Estimated PK Parameter Value t1/2 After PDS Implant Insertion(Randomization to Week 96)
- Estimated PK Parameter Value Cmin(Randomization to Week 96)
- Estimated PK Parameter Value Cmax(Randomization to Week 96)
- Percentage of Participants Who Lose <10 or <5 Letters in BCVA Score From Baseline Over Time(Baseline up to Week 96)
- Baseline Prevalence and Incidence of Treatment-Emergent ADA(Randomization to Week 96)
- Percentage of Participants With BCVA Score of 38 Letters (20/200 Approximate Snellen Equivalent) or Worse at the Average Over Week 36 and Week 40(Baseline, and the average of Week 36 and Week 40)
- Change From Baseline in Center Point Thickness (CPT) at Week 36(Baseline to Week 36)
研究者
研究点 (75)
Loading locations...
相似试验
进行中（未招募）
3 期
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)Neovascular Age-related Macular Degeneration (nAMD)NCT04657289Hoffmann-La Roche451
已完成
3 期
A Clinical Trial to Evaluate Efficacy and Safety of Two Different Formulations of Topical Calcipotriol in Patients With Mild to Moderate Plaque PsoriasisMild to Moderate Plaque PsoriasisNCT05174598Cadila Pharnmaceuticals278
招募中
3 期
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsBreast CancerNCT06079983Jiangsu Alphamab Biopharmaceuticals Co., Ltd400
招募中
3 期
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial CarcinomaUrothelial CarcinomaHER2-expressingNCT05302284RemeGen Co., Ltd.452
Unknown
3 期
A Phase III Study of Ciprofloxacin Plus Fluocinolone in Acute Otitis Externa (AOE)Acute Otitis ExternaNCT04636957Lee's Pharmaceutical Limited600